Trial reportNutrients2023
Efficacy and Safety of MED-01 Probiotics on Vaginal Health: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Trial report in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Effective probiotic regimens for bacterial vaginosis treatment and recurrence prevention: A systematic review.Narra J · 2025Pooled it
- Trial
- Comparative Effects of Intravaginal Progesterone Sponge Durations (Short vs. Long Duration) With or Without Probiotics on Vaginal Microbiota Balance and Reproductive Performance in Black Iraqi Goats.Veterinary medicine international · 2026Article
- Vaginal-spray Bacillus spore probiotics as a potential treatment and reducing recurrence of bacterial vaginosis: randomized, double-blind, and controlled pilot study.Communications medicine · 2025Article
- Recent advances in therapeutic probiotics: insights from human trials.Clinical microbiology reviews · 2025Review
- Gut Microbiome Implication and Modulation in the Management of Recurrent Urinary Tract Infection.Pathogens (Basel, Switzerland) · 2024Review
- Observational
- Review
- Does "all disease begin in the gut"? The gut-organ cross talk in the microbiome.Applied microbiology and biotechnology · 2024Review
- Review
- The human vaginal microbiota: from clinical medicine to models to mechanisms.Current opinion in microbiology · 2024Review
- Role of probiotics in managing various human diseases, from oral pathology to cancer and gastrointestinal diseases.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Bacterial vaginosis (BV) is the most common disease in women of childbearing age and is caused by the growth of abnormal microbiota in the vagina. Probiotic consumption can be an effective alternative treatment to preserve or improve vaginal health. In the present study, MED-01, a complex of five strains of probiotic candidates isolated from the vagina of Korean women, was used. This study was designed as a 12-week, randomized, multicenter, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of MED-01 on vaginal health. A total of 101 reproductive-aged women with a Nugent score of 4-6 took MED-01 (5.0 × 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.